



CIRCULAR 130-18
July 27, 2018

**FINAL CONTRACT ADJUSTMENT
MedReleaf Corp. (LEAF)
Plan of Arrangement (Follow-Up)**

THE FOLLOWING INFORMATION IS PREPARED FOR THE CONVENIENCE OF CANADIAN DERIVATIVES CLEARING CORPORATION (CDCC) MEMBERS AND BOURSE DE MONTRÉAL INC. (THE BOURSE) APPROVED PARTICIPANTS. THIS DOCUMENT IS AN UNOFFICIAL SUMMARY OF CERTAIN TERMS OF THE AFOREMENTIONED ADJUSTMENT. CDCC AND THE BOURSE ACCEPT NO RESPONSIBILITY FOR THE ACCURACY OR COMPLETENESS OF THE SUMMARY. CDCC MEMBERS AND BOURSE APPROVED PARTICIPANTS MUST ENSURE THEY HAVE REVIEWED THE DOCUMENTATION PUBLISHED BY THE ISSUERS INVOLVED IN THIS CORPORATE ACTION.

The Bourse and CDCC wish to inform you that following the information in Circular No. 129-18 and the Notice to Members No. 2018-091 published on July 26, 2018, the new deliverable per ACB1 contract is as follow:

NEW DELIVERABLE PER CONTRACT: 357 common shares of ACB, a cash consideration of 3.425\$CA equivalent to 0.5 ACB share (based on the close of ACB on Thursday July 26, 2018) and a cash consideration of \$0,0001 CAD.

All other adjustment details included in Circular No. 129-18 and the Notice to Members No. 2018-091 remain unchanged.

The cash amount of the deliverable will remain permanently fixed as part of the options deliverable and will not vary.

PLEASE ENSURE THAT ALL CLIENTS WHO HAVE EITHER LONG OR SHORT POSITIONS IN THIS OPTION CLASS ARE ADVISED OF THIS NOTICE.

For further information, please contact Market Operations Department at (514) 871-7877. Clearing members may contact the CDCC Member Services Department.

Gladys Karam
Director, Equity Derivatives
Financial Markets